ClinicalTrials.gov
public full text
Public Domain
Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.
The investigators want to describe the incidence of AKI after CAR-T cells therapy in B-cell lymphoma. With the aim of highlight risk factors in AKI occurrence. Then, look at outcomes in the subgroup with chronic kidney disease at baseline. Finally, the investigators will examine long term evolution of kidney function.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma#435746
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma#1032395
- CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma#844069
- CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.#1126037
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas#349945
Record · ID 1139118
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive